Code No. | M216-3 | |
Anti-TERT (Human) mAb | ||
Size | 100 µL (1 mg/mL) | |
Availability (in Japan) | 10 or more
(In Japan at 17:33, Apr 26, 2024 in JST) |
|
Clonality | Monoclonal | |
Clone | 10E9-2 | |
Isotype (Immunized Animal) |
Mouse IgG2bκ | |
Applications | WB 0.5-10 µg/mL (PMID: 24550003) IP* reported. (PMID: 24550003 / 26830230) IC* reported. (PMID: 24550003) ChIP* Can be used. (PMID: 24550003) |
|
Immunogen (Antigen) |
Recombinant C-terminal His-tagged hTERT protein of 157 amino acids of hTERT (position 304 to 460) | |
Reactivity [Gene ID] | ||
Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | |
Storage temp. | -20°C | |
Conjugate | Unlabeled | |
Manufacturer | MBL | |
Alternative names | TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, PFBMFT1 | |
Background | Human telomerase reverse transcriptase (hTERT) is 1132 amino acids, 127 kDa protein, that is the catalytic subunit of the telomerase. Telomerase is an RNA-dependent DNA polymerase that catalyzes the addition of telomeric repeat unit, 5'-TTAGGG-3', to chromosome ends. Human telomerase consists of three major subunits: TERT, a template RNA called hTR, and telomerase-associated protein (TEP-1). hTERT and hTR are minimally required to reconstitute telomerase activity in vitro. In these subunits, hTR is constitutively expressed; TERT transcription is a primary mechanism for regulation of telomerase activity. In most human somatic cells, telomerase activity is undetectable, whereas approximately 85% of human cancers, including breast, prostate, stomach, bladder, colon, and liver cancer, have telomerase activity. Activation of telomerase is implicated in cell immortalization and cancer cell pathogenesis. | |
Related products | M077-3 Mouse IgG2b (isotype control) |
|
Product category | Research area:Epigenetics Cancer | |
Data | ||
Citations | Western Blotting
ChIP
Immunoprecipitation
Immunocytochemistry
|